NextCell Pharma (NXTCL.ST) Stock Price

NextCell Pharma Price

OMX·CLOSED
0.24
​
Market closed

Over the last 10 years NextCell Pharma grew revenue by 108.8% annually, reaching 10.94 M SEK. For NextCell Pharma, the net margin of -321.3% is up versus -627.9% a few years ago.

NextCell Pharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextCell Pharma business model & stock analysis

NextCell Pharma AB develops stem cell therapies using a proprietary selection algorithm, focusing on autoimmune diabetes and other autoimmune diseases. The company operates a tissue establishment and biobank as a healthcare provider, commercializing mesenchymal stem cell products. Its primary revenue comes from the development and sale of these stem cell therapies to healthcare institutions and research organizations. The firm's business model centers on R&D for stem cell products, with the tissue establishment and biobank supporting its research activities. NextCell targets healthcare providers and research entities as key customers for its stem cell therapies and biobank services. NextCell Pharma AB's revenue streams are derived from the commercialization of its stem cell therapies, leveraging its proprietary technology for autoimmune disease treatment. The company's focus on mesenchymal stem cell products positions it within the healthcare provider segment, specifically serving institutions requiring advanced cell-based treatments.

Frequently asked questions about NextCell Pharma

Converted at the current exchange rate, the NextCell Pharma share trades at 0.02 EUR (0.24 SEK).

The NextCell Pharma share (NXTCL.ST) is listed on 3 stock exchanges, including: Frankfurt (65G.F), Stockholm (NXTCL.ST).

The expected revenue of NextCell Pharma is 12.00 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of NextCell Pharma is -44.56 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of NextCell Pharma is currently -0.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the NextCell Pharma stock.

The price-to-sales ratio (P/S) of NextCell Pharma is currently 2.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the NextCell Pharma stock.

The Eulerpool Quality Score for NextCell Pharma is 5/10.

The ISIN of NextCell Pharma is SE0009723125. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of NextCell Pharma is A2DSXP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of NextCell Pharma is NXTCL.ST. The ticker symbol is used to trade NextCell Pharma shares on the stock exchange.

Fair ValueTerminal
0.20 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Jul 13, 2017
ISIN
SE0009723125
Cusip
W6S1KX105
Market capitalization
26.73 M SEKMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.60
P/Ee 2027
0.14
P/Ee 2028
—
P/S
P/Se
2.23
EV/EBIT
—
P/B Ratio
0.40
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-52.94 %
Last updated Nov 16, 2026, 3:47 AM

NextCell Pharma Peer Group

NextCell Pharma Ticker

FRANKFURT · 65G.FSTOCKHOLM · NXTCL.STSTOCKHOLM · NXTCL.ST

NextCell Pharma FIGI

NXTCL:SF · BBG00GQQ3RY8NXTCLSEK:EP · BBG00W7F8N81NXTCLSEK:EZ · BBG00W7F8NC6NXTCLSEK:XS · BBG00W7F8NF3NXTCLSEK:X2 · BBG00W7F8NG2NXTCLSEK:XH · BBG00W7F8NJ9NXTCLSEK:XF · BBG00W7F8NL6NXTCLSEK:XE · BBG00W7F8NN4NXTCLSEK:XJ · BBG00W7F8NP2NXTCLSEK:XL · BBG00W7F8NQ1NXTCLSEK:XG · BBG00W7F8NR0NXTCLSEK:XO · BBG00W7F8NS9

All fundamentals and in-depth analysis of NextCell Pharma

Our stock analysis for NextCell Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NextCell Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.